ALX Oncology Holdings Inc.

Healthcare · Biotechnology · United States

Last price 1.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 168.70M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre...